Literature DB >> 3478074

Clinical and laboratory features of de novo acute myeloid leukaemia with trilineage myelodysplasia.

F Brito-Babapulle1, D Catovsky, D A Galton.   

Abstract

Primary myelodysplastic syndromes progress to acute myeloid leukaemia (AML) in about 30% of cases. We have sought evidence of pre-existing trilineage myelodysplasia (TMDS) using the FAB criteria (1982) in 160 consecutive cases of primary de novo AML. TMDS was found in 24 cases (15%) including two of 33 cases of M1 (6%), four of 40 cases of M2 (10%), none of 18 cases of M3, five of 31 cases of M4 (15%), six of 30 cases of M5 (20%), all of six cases of M6 and one of two cases of M7. The median presentation bone-marrow blast-cell count in the 24 AML/TMDS cases was 53% (30-90%) and 82% (45-100%) in the 136 cases of AML without TMDS. 60% of the AML/TMDS bone-marrow aspirates contained fewer than 60% of blasts compared with only 11% of those from AML without TMDS (P less than 0.001). In AML the occurrence of symptomatic cytopenias when the marrow blast-cell count is below 60% and the peripheral blood blast-cell count is below 20% is highly correlated with dysplastic haemopoiesis (P less than 0.001).

Entities:  

Mesh:

Year:  1987        PMID: 3478074     DOI: 10.1111/j.1365-2141.1987.tb01325.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  9 in total

Review 1.  Current concerns in haematology. 2: Classification of acute leukaemia.

Authors:  B Bain; D Catovsky
Journal:  J Clin Pathol       Date:  1990-11       Impact factor: 3.411

Review 2.  A classification of acute leukaemia for the 1990s.

Authors:  D Catovsky; E Matutes; V Buccheri; V Shetty; J Hanslip; N Yoshida; R Morilla
Journal:  Ann Hematol       Date:  1991-02       Impact factor: 3.673

3.  Clinical and prognostic investigations on M2/t(8;21) acute nonlymphocytic leukemia.

Authors:  F J Cheng; A D Yang; H B Fei; H Tian
Journal:  J Tongji Med Univ       Date:  1993

4.  Morphological diagnoses of the Japan adult leukemia study group acute myeloid leukemia protocols: central review.

Authors:  K Kuriyama; M Tomonaga; T Kobayashi; J Takeuchi; T Ohshima; S Furusawa; K Saitoh; R Ohno
Journal:  Int J Hematol       Date:  2001-01       Impact factor: 2.490

Review 5.  Stratification of acute myeloid leukemia based on gene expression profiles.

Authors:  Hiroyuki Mano
Journal:  Int J Hematol       Date:  2004-12       Impact factor: 2.490

6.  Reproducibility of the morphological diagnostic criteria for acute myeloid leukemia: the GIMEMA group experience.

Authors:  G L Castoldi; V Liso; S Fenu; M L Vegna; F Mandelli
Journal:  Ann Hematol       Date:  1993-04       Impact factor: 3.673

Review 7.  Treatment concepts for elderly patients with acute myeloid leukemia.

Authors:  Wolfgang R Sperr; Alexander W Hauswirth; Friedrich Wimazal; Paul Knöbl; Klaus Geissler; Peter Valent
Journal:  Wien Klin Wochenschr       Date:  2003-08-14       Impact factor: 1.704

8.  Mitoxantrone and cytosine arabinoside as treatment for acute myeloblastic leukemia in older patients.

Authors:  P K MacCallum; A Z Rohatiner; C L Davis; J S Whelan; A M Oza; J Lim; S Love; J A Amess; M Leahy; R K Gupta
Journal:  Ann Hematol       Date:  1995-07       Impact factor: 3.673

9.  Acute myeloid leukemia with multilineage dysplasia in children.

Authors:  Souichi Adachi; Atsushi Manabe; Masue Imaizumi; Takashi Taga; Akio Tawa; Masahito Tsurusawa; Akira Kikuchi; Atsuko Masunaga; Masahiro Tsuchida; Tatsutoshi Nakahata
Journal:  Int J Hematol       Date:  2007-11       Impact factor: 2.490

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.